MADRIGAL PHARMACEUTICALS, INC. Operating Lease Cost
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Operating Lease Cost of $1.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2019-12-31 was $119.00K.
- MADRIGAL PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2019-09-30 was $93.00K.
- MADRIGAL PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2019-06-30 was $117.00K.
- MADRIGAL PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2019-03-31 was $57.00K.
- MADRIGAL PHARMACEUTICALS, INC. operating lease, cost for fiscal 2025 was $1.90M, a 111.11% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. operating lease, cost for fiscal 2024 was $900.00K, a 18.18% decline from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. operating lease, cost for fiscal 2023 was $1.10M, a 37.50% increase from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. operating lease, cost for fiscal 2022 was $800.00K, a 100.00% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.90M 10-K · filed 2026-02-19 | ||||
| 2024-12-31 | $900.00K 10-K · filed 2026-02-19 | ||||
| 2023-12-31 | $1.10M 10-K · filed 2026-02-19 | ||||
| 2022-12-31 | $800.00K 10-K · filed 2024-02-28 | ||||
| 2021-12-31 | $400.00K 10-K/A · filed 2023-03-03 | ||||
| 2020-12-31 | $300.00K 10-K · filed 2022-02-24 | $347.00K 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $212.00K derived: sum of 2 quarters · filed 2021-02-25 | $329.00K derived: sum of 3 quarters · filed 2021-02-25 | $386.00K 10-K · filed 2021-02-25 | |
| 2019-09-30 | $93.00K 10-Q · filed 2019-11-06 | $210.00K derived: sum of 2 quarters · filed 2019-11-06 | $267.00K 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | $117.00K 10-Q · filed 2019-08-07 | $174.00K 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $57.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |